Treatment of pseudomonas and staphylococcus bronchopulmonary infection in patients with cystic fibrosis

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Das, Rashmi Ranjan ^a   Kabra, Sushil Kumar ^a   Singh, Meenu ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; AZTREONAM LYSINE; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; GLYCOPEPTIDE; PENICILLIN DERIVATIVE; PLACEBO; QUINOLONE DERIVATIVE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; COHORT ANALYSIS; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; IN VITRO STUDY; LUNG FUNCTION; MEDICATION THERAPY MANAGEMENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY (TOPIC); PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION ROUTE; META ANALYSIS; MICROBIOLOGY; REGISTER;

ANTI-BACTERIAL AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; DRUG ADMINISTRATION ROUTES; HUMANS; PSEUDOMONAS INFECTIONS; REGISTRIES; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

EID: 84896345220     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/645653     Document Type: Review

References (86)

1. O'Sullivan B. P., Freedman S. D., Cystic fibrosis. The Lancet 2009 373 9678 1891 1904 2-s2.0-65849522497 10.1016/S0140-6736(09)60327-5
2. McCoy K. S., Quittner A. L., Oermann C. M., Gibson R. L., Retsch-Bogart G. Z., Montgomery A. B., Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2008 178 9 921 928 2-s2.0-55549137086 10.1164/rccm.200712-1804OC
3. Retsch-Bogart G. Z., Burns J. L., Otto K. L., Liou T. G., McCoy K., Oermann C., Gibson R. L., A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatric Pulmonology 2008 43 1 47 58 2-s2.0-38349058630 10.1002/ppul.20736
4. Retsch-Bogart G. Z., Quittner A. L., Gibson R. L., Oermann C. M., McCoy K. S., Montgomery A. B., Cooper P. J., Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009 135 5 1223 1232 2-s2.0-65949124667 10.1378/chest.08-1421
5. Oermann C. M., Retsch-bogart G. Z., Quittner A. L., Gibson R. L., Mccoy K. S., Montgomery A. B., Cooper P. J., An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatric Pulmonology 2010 45 11 1121 1134 2-s2.0-78449294500 10.1002/ppul.21301
6. Wainwright C. E., Quittner A. L., Geller D. E., Nakamura C., Wooldridge J. L., Gibson R. L., Lewis S., Montgomery A. B., Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. Journal of Cystic fibrosis 2011 10 4 234 242 2-s2.0-79958295843 10.1016/j.jcf.2011.02.007
7. Chuchalin A., Csiszér E., Gyurkovics K., Bartnicka M. T., Sands D., Kapranov N., Varoli G., Preti P. A. M., Mazurek H., A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatric Drugs 2007 9 1 21 31 2-s2.0-34249945743 10.2165/00148581-200709001-00004 (Pubitemid 46879111)
8. Lenoir G., Antypkin Y. G., Miano A., Moretti P., Zanda M., Varoli G., Preti P. A. M., Aryayev N. L., Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatric Drugs 2007 9 1 11 20 2-s2.0-34249938781 (Pubitemid 46879110)
9. MacLusky I. B., Gold R., Corey M., Levison H., Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatric pulmonology 1989 7 1 42 48 2-s2.0-0024331219
10. Murphy T. D., Anbar R. D., Lester L. A., Nasr S. Z., Nickerson B., VanDevanter D. R., Colin A. A., Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatric Pulmonology 2004 38 4 314 320 2-s2.0-4544269731 10.1002/ppul.20097 (Pubitemid 39245114)
11. Ramsey B. W., Dorkin H. L., Eisenberg J. D., Gibson R. L., Harwood I. R., Kravitz R. M., Schidlow D. V., Wilmott R. W., Astley S. J., McBurnie M. A., Wentz K., Smith A. L., Efficacy of aerosolized tobramycin in patients with cystic fibrosis. The New England Journal of Medicine 1993 328 24 1740 1746 2-s2.0-0027287651 10.1056/NEJM199306173282403 (Pubitemid 23170123)
12. Ramsey W. B., Pepe M. S., Quan J. M., Intermittent administration of inhaled tobramycin in patients with cvstic fibrosis. Pneumologie 1999 53 4 239 2-s2.0-33748190399
13. Moss R. B., Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002 121 1 55 63 2-s2.0-0036157901 10.1378/chest.121.1.55 (Pubitemid 34114228)
14. Stelmach I., Korzeniewska A., Stelmach W., Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Respiration 2008 75 2 178 181 2-s2.0-40549095341 10.1159/000101725 (Pubitemid 351363872)
15. Galeva I., Konstan M. W., Higgins M., Angyalosi G., Brockhaus F., Piggott S., Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Current Medical Research and Opinion 2013 29 8 947 956
16. Konstan M. W., Geller D. E., Minić P., Brockhaus F., Zhang J., Angyalosi G., Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatric Pulmonology 2011 46 3 230 238 2-s2.0-79951840468 10.1002/ppul.21356
17. Jensen T., Pedersen S. S., Garne S., Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Journal of Antimicrobial Chemotherapy 1987 19 6 831 838 2-s2.0-0023265976 (Pubitemid 17092071)
18. Day A. J., Williams J., McKeown C., Bruton A., Weller P. H., Evaluation of inhaled colomycin in children with cystic Fibrosis. Proceedings of the 10th International Cystic fibrosis Congress 1988
19. Nikonova V., Zhekayte E., Kapranov N., Efficacy and safety of colistin for inhalation in children 5 years old and younger with cystic fibrosis with Pseudomonas aeruginosa infection. Journal of Cystic fibrosis 2005 4 S100
20. Wolter J., Seeney S., Bell S., Bowler S., Masel P., McCormack J., Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002 57 3 212 216 2-s2.0-0036185807 10.1136/thorax.57.3.212 (Pubitemid 34214405)
21. Equi A., Balfour-Lynn I. M., Bush A., Rosenthal M., Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. The Lancet 2002 360 9338 978 984 2-s2.0-0037190575 10.1016/S0140-6736(02)11081-6 (Pubitemid 35284109)
22. Saiman L., Marshall B. C., Mayer-Hamblett N., Burns J. L., Quittner A. L., Cibene D. A., Coquillette S., Fieberg A. Y., Accurso F. J., Campbell P. W. III, Azithromycin in patients with cystic fibrosis chronically Infected with Pseudomonas aeruginosa: a randomized controlled trial. Journal of the American Medical Association 2003 290 13 1749 1756 2-s2.0-0141816759 10.1001/jama.290.13. 1749 (Pubitemid 37430625)
23. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., Jais J.-P., Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006 61 10 895 902 2-s2.0-33749984264 10.1136/thx.2005.057950 (Pubitemid 44570311)
24. Steinkamp G., Schmitt-Grohe S., Döring G., Staab D., Pfründer D., Beck G., Schubert R., Zielen S., Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine 2008 102 11 1643 1653 2-s2.0-55549129249 10.1016/j.rmed.2008.03.009
25. Saiman L., Anstead M., Mayer-Hamblett N., Lands L. C., Kloster M., Hocevar-Trnka J., Goss C. H., Rose L. M., Burns J. L., Marshall B. C., Ratjen F., Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. Journal of the American Medical Association 2010 303 17 1707 1715 2-s2.0-77951887288 10.1001/jama.2010.563
26. Loening-Baucke V. A., Mischler E., Myers M. G., A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. Journal of Pediatrics 1979 95 4 630 637 2-s2.0-0018294305 (Pubitemid 9247455)
27. Weaver L. T., Green M. R., Nicholson K., Mills J., Heeley M. E., Kuzemko J. A., Austin S., Gregory G. A., Dux A. E. W., Davis J. A., Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Archives of Disease in Childhood 1994 70 2 84 89 2-s2.0-0028350689 (Pubitemid 24088956)
28. Nolan G., McIvor P., Levison H., Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. Journal of Pediatrics 1982 101 4 626 630 2-s2.0-0019987826 (Pubitemid 12028542)
29. Ratjen F., Comes G., Paul K., Posselt H. G., Wagner T. O., Harms K., German Board of the European Registry for Cystic fibrosis (ERCF). Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatric Pulmonology 2001 31 1 13 16 (Pubitemid 32154735)
30. Stutman H. R., Lieberman J. M., Nussbaum E., Marks M. I., Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. Journal of Pediatrics 2002 140 3 299 305 2-s2.0-0036220978 10.1067/mpd.2002.121930 (Pubitemid 34289705)
31. Solís A., Brown D., Hughes J., Van Saene H. K. F., Heaf D. P., Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatric Pulmonology 2003 36 3 189 195 2-s2.0-0041353728 10.1002/ppul.10231 (Pubitemid 37055965)
32. Macfarlane M., Leavy A., McCaughan J., Fair R., Reid A. J. M., Successful decolonization of meticillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. Journal of Hospital Infection 2007 65 3 231 236 2-s2.0-33847047400 10.1016/j.jhin.2006.10. 011
33. Garske L. A., Kidd T. J., Gan R., Bunting J. P., Franks C. A., Coulter C., Masel P. J., Bell S. C., Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. Journal of Hospital Infection 2004 56 3 208 214 2-s2.0-1342286303 10.1016/j.jhin.2003.12.003 (Pubitemid 38262949)
34. Halton K., Zobell J., MacKay M., Ensign R., Chatfield B. A., Evaluation of the effectiveness of a MRSA eradication protocol in pediatric CF patients. Pediatric Pulmonology 2009 32 339
35. Vanderhelst E., De Wachter E., Willekens J., Piérard D., Vincken W., Malfroot A., Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of 11 patients. Journal of Cystic Fibrosis 2013 12 6 662 666 10.1016/j.jcf.2013.04.009
36. Hewer S. C. L., Smyth A. R., Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2009 7 4 2-s2.0-75349112811
37. Wiesemann H. G., Steinkamp G., Ratjen F., Placebo-controlled, double-blind, randomized study of aerolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatric Pulmonology 1998 25 2 88 92 (Pubitemid 28110583)
38. Gibson R. L., Emerson J., McNamara S., Burns J. L., Rosenfeld M., Yunker A., Hamblett N., Accurso F., Dovey M., Hiatt P., Konstan M. W., Moss R., Retsch-Bogart G., Wagener J., Waltz D., Wilmott R., Zeitlin P. L., Ramsey B., Cohen M., Foster J., Hallmark C., Hasbrouck T., Hilliard J., Hilliard K., Ingham L., Johnson C., Kociela V., Kronmal R., Locke S., Mundahl J., Osberg I., Penvari C., Stapp J., Watts S., Wertz M., Williams J., Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003 167 6 841 849 2-s2.0-0037445216 10.1164/rccm.200208-855OC (Pubitemid 36801771)
39. Proesmans M., Vermeulen F., Boulanger L., Verhaegen J., De Boeck K., Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic fibrosis 2013 12 1 29 34
40. Ratjen F., Doring G., Nikolaizik W. H., Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. The Lancet 2001 358 9286 983 984 2-s2.0-0035934545 10.1016/S0140-6736(01)06124-4 (Pubitemid 32913526)
41. Gibson R. L., Emerson J., Mayer-Hamblett N., Burns J. L., McNamara S., Accurso F. J., Konstan M. W., Chatfield B. A., Retsch-Bogart G., Waltz D. A., Acton J., Zeitlin P., Hiatt P., Moss R., Williams J., Ramsey B. W., Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatric Pulmonology 2007 42 7 610 623 2-s2.0-34347370866 10.1002/ppul.20625 (Pubitemid 47022973)
42. Ratjen F., Munck A., Kho P., Angyalosi G., Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010 65 4 286 291 2-s2.0-77950914953 10.1136/thx.2009.121657
43. Treggiari M. M., Retsch-Bogart G., Mayer-Hamblett N., Khan U., Kulich M., Kronmal R., Williams J., Hiatt P., Gibson R. L., Spencer T., Orenstein D., Chatfield B. A., Froh D. K., Burns J. L., Rosenfeld M., Ramsey B. W., Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Pediatrics and Adolescent Medicine 2011 165 9 847 856 2-s2.0-80052511405 10.1001/archpediatrics.2011.136
44. Taccetti G., Bianchini E., Cariani L., Buzzetti R., Costantini D., Trevisan F., Zavataro L., Campana S., Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 2012 67 10 853 859 2-s2.0-84857488379 10.1136/thoraxjnl-2011-200832
45. Littlewood J. M., Miller M. G., Ghoneim A. T., Ramsden C. H., Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. The Lancet 1985 1 8433 865 2-s2.0-0021996644 (Pubitemid 15115129)
46. Valerius N. H., Koch C., Hoiby N., Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. The Lancet 1991 338 8769 725 726 2-s2.0-0025868478 10.1016/0140-6736(91)91446-2
47. Frederiksen B., Koch C., Høiby N., Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatric Pulmonology 1997 23 5 330 335 (Pubitemid 27225208)
48. Hansen C. R., Pressler T., Høiby N., Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. Journal of Cystic Fibrosis 2008 7 6 523 530 2-s2.0-55549102981 10.1016/j.jcf.2008.06.009
49. Schelstraete P., Deschaght P., Van Simaey L., Van daele S., Haerynck F., Vaneechoutte M., De Baets F., Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients. Journal of Cystic Fibrosis 2010 9 2 99 103 2-s2.0-76749139465 10.1016/j.jcf.2009.11.006
50. Vazquez C., Municio M., Corera M., Gaztelurrutia L., Sojo A., Vitoria J. C., Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatrica, International Journal of Paediatrics 1993 82 3 308 309 2-s2.0-0027401310 (Pubitemid 23107556)
51. Steinkamp G., Tummler B., Malottke R., Von der Hardt H., Treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Archives of Disease in Childhood 1989 64 7 1022 1028 2-s2.0-0024308071 (Pubitemid 19177590)
52. Munck A., Bonacorsi S., Mariani-Kurkdjian P., Lebourgeois M., Gérardin M., Brahimi N., Navarro J., Bingen E., Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatric Pulmonology 2001 32 4 288 292 2-s2.0-0034785372 10.1002/ppul.1121 (Pubitemid 32938877)
53. Griese M., Müller I., Reinhardt D., Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis. European journal of medical research 2002 7 2 79 80 2-s2.0-0037148986
54. Nixon G. M., Armstrong D. S., Carzino R., Carlin J. B., Olinsky A., Robertson C. F., Grimwood K., Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Pediatrics 2001 138 5 699 704 2-s2.0-0035002870 10.1067/mpd.2001.112897 (Pubitemid 32417671)
55. Douglas T. A., Brennan S., Berry L., Winfield K., Wainwright C. E., Grimwood K., Stick S. M., Sly P. D., Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax 2010 65 11 985 990 2-s2.0-78149361309 10.1136/thx.2009.132845
56. Stuart B., Lin J. H., Mogayzel P. J., Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatric Respiratory Reviews 2010 11 3 177 184 2-s2.0-77955413607 10.1016/j.prrv.2010.05.003
57. Ryan G., Singh M., Dwan K., Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database of Systematic Reviews 2011 16 3 2-s2.0-79953284775 10.1002/14651858
58. Assael B. M., Pressler T., Bilton D., Fayon M., Fischer R., Chiron R., Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. Journal of Cystic fibrosis 2013 12 2 130 140 10.1016/j.jcf.2012.07.006
59. Trapnell B. C., McColley S. A., Kissner D. G., Rolfe M. W., Rosen J. M., McKevitt M., Moorehead L., Montgomery A. B., Geller D. E., Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. American Journal of Respiratory and Critical Care Medicine 2012 185 2 171 178 2-s2.0-84856010859 10.1164/rccm.201105-0924OC
60. Hodson M. E., Gallagher C. G., Govan J. R. W., A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. European Respiratory Journal 2002 20 3 658 664 2-s2.0-0036736583 10.1183/09031936.02. 00248102
61. Schuster A., Haliburn C., Döring G., Goldman M. H., Freedom Study Group. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013 68 4 344 350
62. Geller D. E., Flume P. A., Staab D., Fischer R., Loutit J. S., Conrad D. J., Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine 2011 183 11 1510 1516 2-s2.0-79957942626 10.1164/rccm.201008-1293OC
63. Hodson M. E., Penketh A. R. L., Batten J. C., Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. The Lancet 1981 2 8256 1137 1139 2-s2.0-0019511799 (Pubitemid 11029642)
64. Kun P., Landau L. I., Phelan P. D., Nebulized gentamicin in children and adolescents with cystic fibrosis. Australian Paediatric Journal 1984 20 1 43 45 2-s2.0-0021244064 (Pubitemid 14123235)
65. Nathanson I., Cropp G. J. A., Li P., Neter P., Effectiveness of aerosolized gentamicin in cystic fibrosis (CF). Cystic Fibrosis Club Abstracts 1985 28 145
66. Stead R. J., Hodson M. E., Batten J. C., Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. British Journal of Diseases of the Chest 1987 81 3 272 279 2-s2.0-0023219505 (Pubitemid 17091811)
67. Sheldon C. D., Assoufi B. K., Hodson M. E., Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Respiratory Medicine 1993 87 8 587 593 2-s2.0-0027492890 10.1016/S0954-6111(05)80261-6 (Pubitemid 23350167)
68. Schaad U. B., Wedgwood J., Ruedeberg A., Kraemer R., Hampel B., Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatric Infectious Disease Journal 1997 16 1 106 111 2-s2.0-0031041350 10.1097/00006454-199701000-00032 (Pubitemid 27063128)
69. Jensen T., Pedersen S. S., Nielsen C. H., Hoiby N., Koch C., The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1987 20 4 585 594 2-s2.0-0023280807 (Pubitemid 17154600)
70. Jensen T., Pedersen S. S., Hoiby N., Koch C., Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. European Journal of Clinical Microbiology 1987 6 6 618 622 2-s2.0-0023470681 (Pubitemid 18000962)
71. Carswell F., Ward C., Cook D. A., Speller D. C. E., A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. British Journal of Diseases of the Chest 1987 81 4 356 360 2-s2.0-0023628903 (Pubitemid 17164863)
72. Latzin P., Fehling M., Bauernfeind A., Reinhardt D., Kappler M., Griese M., Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. Journal of Cystic fibrosis 2008 7 2 142 146 2-s2.0-40649105285 10.1016/j.jcf.2007.07.001 (Pubitemid 351372759)
73. Lai H. J., Cheng Y., Farrell P. M., The survival advantage of patients with cystic fibrosis diagnosed through neonatal screening: evidence from the United States cystic fibrosis Foundation Registry data. Journal of Pediatrics 2005 147 3 S57 S63 2-s2.0-25844466580 10.1016/j.jpeds.2005.08.014 (Pubitemid 41400260)
74. Goerke C., Kraning K., Stern M., Döring G., Botzenhart K., Wolz C., Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fibrosis patients. Journal of Infectious Diseases 2000 181 3 984 989 2-s2.0-0034113631 10.1086/315331 (Pubitemid 30194482)
75. Mainz J. G., Naehrlich L., Schien M., Käding M., Schiller I., Mayr S., Schneider G., Wiedemann B., Wiehlmann L., Cramer N., Pfister W., Kahl B. C., Beck J. F., Tümmler B., Concordant genotype of upper and lower airways P. aeruginosa and S. aureus isolates in cystic fibrosis. Thorax 2009 64 6 535 540 2-s2.0-67249139656 10.1136/thx.2008.104711
76. Wolter D. J., Emerson J. C., McNamara S., Buccat A. M., Qin X., Cochrane E., Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clinical Infectious Diseases 2013 57 3 384 391
77. Besier S., Smaczny C., Von Mallinckrodt C., Krahl A., Ackermann H., Brade V., Wichelhaus T. A., Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. Journal of Clinical Microbiology 2007 45 1 168 172 2-s2.0-33846356800 10.1128/JCM.01510-06 (Pubitemid 46127347)
78. Szaff M., Hoiby N., Antibiotic treatment of Staphyloccus aureus infection in cystic fibrosis. Acta Paediatrica Scandinavica 1982 71 5 821 826 2-s2.0-0019961926 (Pubitemid 12049540)
79. Jensen T., Lanng S., Faber M., Rosdahl V. T., Hoiby N., Koch C., Clinical experiences with fusidic acid in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 1990 25 45 52 2-s2.0-0025231783 (Pubitemid 20087266)
80. Doring G., Hoiby N., Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. Journal of Cystic fibrosis 2004 3 2 67 91 (Pubitemid 38987019)
81. Smyth A., Walters S., Prophylactic antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2003 3 2-s2.0-0141724887
82. Flume P. A., O'Sullivan B. P., Robinson K. A., Goss C. H., Mogayzel P. J. Jr., Willey-Courand D. B., Bujan J., Finder J., Lester M., Quittell L., Rosenblatt R., Vender R. L., Hazle L., Sabadosa K., Marshall B., Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine 2007 176 10 957 969 2-s2.0-36248953255 10.1164/rccm.200705-664OC (Pubitemid 350127838)
83. Máiz L., Del Campo R., Castro M., Gutiérrez D., Girón R., Moreno R. C., Maintenance treatment with inhaled ampicillin in patients with cystic fibrosis and lung infection due to methicillin-sensitive Staphylococcus aureus. Archivos de Bronconeumología 2012 48 10 384
84. Goss C. H., Muhlebach M. S., Review: Staphylococcus aureus and MRSA in cystic fibrosis. Journal of Cystic fibrosis 2011 10 5 298 306 2-s2.0-80052458914 10.1016/j.jcf.2011.06.002
85. Cantón R., Cobos N., de Gracia J., Baquero F., Honorato J., Gartner S., Alvarez A., Salcedo A., Oliver A., García-Quetglas E., Dapena J., Máiz L., Vázquez C., Antelo C., Martínez- Martínez L., Honorato J., Borderías L., Vendrell M., Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clinical Microbiology and Infection 2005 11 9 690 703 2-s2.0-23844474727 10.1111/j.1469-0691.2005.01217.x (Pubitemid 41167334)
86. Máiz L., Girón R. M., Olveira C., Quintana E., Lamas A., Pastor D., Cantón R., Mensa J., Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opinion on Pharmacotherapy 2013 14 9 1135 1149